Laboratorios Rovi

Rovi nuevita

Laboratorios Rovi’s Acquisition of CDMO plant in US provides attractive opportunity for profitable growth

Banc Sabadell | From the meeting held by the management of Laboratorios Rovi (ROVI) to explain the acquisition of a CDMO plant in the United States, we highlight the following messages: They do not expect the CDMO plant to be accretive to earnings for a couple of years, but they do expect a significant increase in profitability with the entry of new customers in the pre-filled syringe line. In any…


Rovi 300x154 1

Rovi acquires pharmaceutical manufacturing plant in Arizona from Bristol Myers Squibb

Bankinter | The company is acquiring a drug manufacturing plant in the United States. The seller of the plant is Bristol Myers Squibb, and it is located in Phoenix, Arizona. Rovi has signed a manufacturing agreement with Bristol Myers Squibb for an initial term of five years and a minimum payment of $50 million for each year of the contract. The purchase price has not been disclosed, but according to…


grifols edificio

Neither Grifols, Rovi nor Almirall to be significantly affected by tariffs on pharmaceutical sector

Banc Sabadell | Trump said on social media that, starting on 1 October, all branded or patented pharmaceutical products will be subject to a 100% tariff, unless the company has begun to build a manufacturing facility in the United States. Assessment: Negative news due to the noise it may generate. However, details remain to be finalised, as we do not know whether companies that already had a presence in the…


Rovi 300x154 1

Rovi affected by ‘noise’ surrounding vaccine manufacturers: FDA plans to link deaths of 25 children to Covid vaccines

Banco Sabadell | According to press reports, the FDA is planning to publish a report linking the deaths of 25 children to Covid vaccines. Assessment: Negative news due to the ‘noise’ it generates around vaccine manufacturers, something that has become commonplace since Trump appointed Robert F. Kennedy (a well-known anti-vaccine advocate) to head the FDA. We continue to believe that vaccination rates in the US, once the endemic phase has…


Rovi nuevita

Laboratorios Rovi’s gross margin could reach 63% thanks to lower raw material costs and higher sales of Okedi

Renta 4 | Laboratorios Rovi (ROVI) will publish its Q2 2025 results on Thursday 24 July at 10 a.m. We expect some improvement on the figures recorded in the previous quarter, although it is true that the year-on-year comparison in this second quarter is much more challenging, and in this regard, Rovi will present figures that, at first glance, appear worse. Thus, we expect Rovi to report revenues of €160…


Rovi nuevita

Rovi Laboratories shows brilliant revenue growth, 1.5-1.8x in sight

Jefferies | Rovi Laboratories (ROVI), ahead of its CMD (9am UKT), has announced a revenue forecast for FY30E of 1.5-1.8 times FY24 levels, a midpoint of €1.261 billion (up 10% versus estimated JEF €1.144 billion). This growth is driven by the forecast of a two-fold increase in CDMO revenues in 24, to around €700 million in 2030E (up 60% compared to €429 million in 2005). Including the additional €250 million…


ROVI MODERNA

Rovi issues profit warning: EBITDA to be 10-15% lower than consensus expectations; P.O. lowered to €60.10/share from €73/share

Bankinter: In a Significant Event, Rovi announced that it expects its EBITDA 2024 to be lower, in a range between 10% and 15%, than expected by the market. The company will publish its annual results on 25 February. It maintains its forecasts for the current financial year 2025 (Sales down 10%/0%). Analysis team’s opinion: Negative news. Consensus market estimates indicate sales 2024 of €787m (down 5% year-on-year) which is in…


ROVI MODERNA

Laboratorios Rovi negotiates sale of third-party manufacturing business, valued at over €3 billion, with CVC

Bankinter | Laboratorios Rovi (ROVI) is negotiating with the CVC fund the sale of its third-party manufacturing business. The valuation of 100% of this business could exceed €3,000 million. Antin, Cinven, KKR and Permira have dropped out of the bidding. Opinion of Bankinter’s analysis team: Positive news that opens the possibility for Rovi to value its assets, the first glimpses of which we saw in March. Sales of the manufacturing…